Myelodysplastic syndromes: Clinical Practice Guidelines in Oncology

Peter L. Greenberg, Maria R. Baer, John M. Bennett, Clara D. Bloomfield, Carlos M. De Castro, H. Joachim Deeg, Marcel P DeVetten, Peter D. Emanuel, Harry P. Erba, Eli Estey, James Foran, Steven D. Gore, Michael Millenson, Willlis H. Navarro, Stephen D. Nimer, Margaret R. O'Donnell, Hussain I. Saba, Kathy Spiers, Richard M. Stone, Martin S. Tallman

Research output: Contribution to journalReview article

45 Citations (Scopus)

Abstract

These suggested practice guidelines are based on extensive evaluation of the reviewed risk-based data and indicate useful current approaches for managing patients with MDS. Given the limited number of studies comparing different therapies in MDS, most of the therapeutic drugs used to treat this disease should be assessed in the context of clinical trials. Several clinical trials are ongoing to assess the efficacy of novel biospecific agents in this disease. The role of thrombopoietic cytokines for management of thrombocytopenia in MDS needs further evaluation. In addition, further determination of the effects of these therapeutic interventions on the patient's quality of life is important. Progress toward improving management of MDS has occurred over the past few years, and more such advances are anticipated using these guidelines as a framework for coordination of comparative clinical trials.

Original languageEnglish (US)
Pages (from-to)58-77
Number of pages20
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume4
Issue number1
StatePublished - Jan 1 2006

Fingerprint

Myelodysplastic Syndromes
Practice Guidelines
Clinical Trials
Therapeutic Uses
Thrombocytopenia
Quality of Life
Guidelines
Cytokines
Therapeutics
Pharmaceutical Preparations

Keywords

  • Chronic myelomonocytic leukemia
  • Cytopenias
  • Myelodysplastic syndromes
  • NCCN Clinical Practice Guidelines
  • Refractory anemia
  • Treatment

ASJC Scopus subject areas

  • Oncology

Cite this

Greenberg, P. L., Baer, M. R., Bennett, J. M., Bloomfield, C. D., De Castro, C. M., Deeg, H. J., ... Tallman, M. S. (2006). Myelodysplastic syndromes: Clinical Practice Guidelines in Oncology. JNCCN Journal of the National Comprehensive Cancer Network, 4(1), 58-77.

Myelodysplastic syndromes : Clinical Practice Guidelines in Oncology. / Greenberg, Peter L.; Baer, Maria R.; Bennett, John M.; Bloomfield, Clara D.; De Castro, Carlos M.; Deeg, H. Joachim; DeVetten, Marcel P; Emanuel, Peter D.; Erba, Harry P.; Estey, Eli; Foran, James; Gore, Steven D.; Millenson, Michael; Navarro, Willlis H.; Nimer, Stephen D.; O'Donnell, Margaret R.; Saba, Hussain I.; Spiers, Kathy; Stone, Richard M.; Tallman, Martin S.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 4, No. 1, 01.01.2006, p. 58-77.

Research output: Contribution to journalReview article

Greenberg, PL, Baer, MR, Bennett, JM, Bloomfield, CD, De Castro, CM, Deeg, HJ, DeVetten, MP, Emanuel, PD, Erba, HP, Estey, E, Foran, J, Gore, SD, Millenson, M, Navarro, WH, Nimer, SD, O'Donnell, MR, Saba, HI, Spiers, K, Stone, RM & Tallman, MS 2006, 'Myelodysplastic syndromes: Clinical Practice Guidelines in Oncology', JNCCN Journal of the National Comprehensive Cancer Network, vol. 4, no. 1, pp. 58-77.
Greenberg PL, Baer MR, Bennett JM, Bloomfield CD, De Castro CM, Deeg HJ et al. Myelodysplastic syndromes: Clinical Practice Guidelines in Oncology. JNCCN Journal of the National Comprehensive Cancer Network. 2006 Jan 1;4(1):58-77.
Greenberg, Peter L. ; Baer, Maria R. ; Bennett, John M. ; Bloomfield, Clara D. ; De Castro, Carlos M. ; Deeg, H. Joachim ; DeVetten, Marcel P ; Emanuel, Peter D. ; Erba, Harry P. ; Estey, Eli ; Foran, James ; Gore, Steven D. ; Millenson, Michael ; Navarro, Willlis H. ; Nimer, Stephen D. ; O'Donnell, Margaret R. ; Saba, Hussain I. ; Spiers, Kathy ; Stone, Richard M. ; Tallman, Martin S. / Myelodysplastic syndromes : Clinical Practice Guidelines in Oncology. In: JNCCN Journal of the National Comprehensive Cancer Network. 2006 ; Vol. 4, No. 1. pp. 58-77.
@article{a141ac682c5e469cae66fbe89781c93d,
title = "Myelodysplastic syndromes: Clinical Practice Guidelines in Oncology",
abstract = "These suggested practice guidelines are based on extensive evaluation of the reviewed risk-based data and indicate useful current approaches for managing patients with MDS. Given the limited number of studies comparing different therapies in MDS, most of the therapeutic drugs used to treat this disease should be assessed in the context of clinical trials. Several clinical trials are ongoing to assess the efficacy of novel biospecific agents in this disease. The role of thrombopoietic cytokines for management of thrombocytopenia in MDS needs further evaluation. In addition, further determination of the effects of these therapeutic interventions on the patient's quality of life is important. Progress toward improving management of MDS has occurred over the past few years, and more such advances are anticipated using these guidelines as a framework for coordination of comparative clinical trials.",
keywords = "Chronic myelomonocytic leukemia, Cytopenias, Myelodysplastic syndromes, NCCN Clinical Practice Guidelines, Refractory anemia, Treatment",
author = "Greenberg, {Peter L.} and Baer, {Maria R.} and Bennett, {John M.} and Bloomfield, {Clara D.} and {De Castro}, {Carlos M.} and Deeg, {H. Joachim} and DeVetten, {Marcel P} and Emanuel, {Peter D.} and Erba, {Harry P.} and Eli Estey and James Foran and Gore, {Steven D.} and Michael Millenson and Navarro, {Willlis H.} and Nimer, {Stephen D.} and O'Donnell, {Margaret R.} and Saba, {Hussain I.} and Kathy Spiers and Stone, {Richard M.} and Tallman, {Martin S.}",
year = "2006",
month = "1",
day = "1",
language = "English (US)",
volume = "4",
pages = "58--77",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "1",

}

TY - JOUR

T1 - Myelodysplastic syndromes

T2 - Clinical Practice Guidelines in Oncology

AU - Greenberg, Peter L.

AU - Baer, Maria R.

AU - Bennett, John M.

AU - Bloomfield, Clara D.

AU - De Castro, Carlos M.

AU - Deeg, H. Joachim

AU - DeVetten, Marcel P

AU - Emanuel, Peter D.

AU - Erba, Harry P.

AU - Estey, Eli

AU - Foran, James

AU - Gore, Steven D.

AU - Millenson, Michael

AU - Navarro, Willlis H.

AU - Nimer, Stephen D.

AU - O'Donnell, Margaret R.

AU - Saba, Hussain I.

AU - Spiers, Kathy

AU - Stone, Richard M.

AU - Tallman, Martin S.

PY - 2006/1/1

Y1 - 2006/1/1

N2 - These suggested practice guidelines are based on extensive evaluation of the reviewed risk-based data and indicate useful current approaches for managing patients with MDS. Given the limited number of studies comparing different therapies in MDS, most of the therapeutic drugs used to treat this disease should be assessed in the context of clinical trials. Several clinical trials are ongoing to assess the efficacy of novel biospecific agents in this disease. The role of thrombopoietic cytokines for management of thrombocytopenia in MDS needs further evaluation. In addition, further determination of the effects of these therapeutic interventions on the patient's quality of life is important. Progress toward improving management of MDS has occurred over the past few years, and more such advances are anticipated using these guidelines as a framework for coordination of comparative clinical trials.

AB - These suggested practice guidelines are based on extensive evaluation of the reviewed risk-based data and indicate useful current approaches for managing patients with MDS. Given the limited number of studies comparing different therapies in MDS, most of the therapeutic drugs used to treat this disease should be assessed in the context of clinical trials. Several clinical trials are ongoing to assess the efficacy of novel biospecific agents in this disease. The role of thrombopoietic cytokines for management of thrombocytopenia in MDS needs further evaluation. In addition, further determination of the effects of these therapeutic interventions on the patient's quality of life is important. Progress toward improving management of MDS has occurred over the past few years, and more such advances are anticipated using these guidelines as a framework for coordination of comparative clinical trials.

KW - Chronic myelomonocytic leukemia

KW - Cytopenias

KW - Myelodysplastic syndromes

KW - NCCN Clinical Practice Guidelines

KW - Refractory anemia

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=33645057481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645057481&partnerID=8YFLogxK

M3 - Review article

C2 - 16403405

AN - SCOPUS:33645057481

VL - 4

SP - 58

EP - 77

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 1

ER -